When was Relation founded?

Relation was founded in 2019 and raised its 1st funding round 2 years after it was founded.

Where is Relation located?

Relation is headquartered in London, United Kingdom.

How many employees does Relation have?

As of Sep 30, 2026, the latest employee count at Relation is 148.

Is Relation a funded company?

Relation is a funded company, having raised a total of $116M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 10, 2021.

When was the latest funding round of Relation?

Relation's latest funding was a $***** Seed round on Nov 21, 2025, with participation from 3 investors.

Where does Relation rank among its competitors?

Relation ranks 44th amongst 3052 active competitors, of which 1053 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Relation?

Relation's top competitors include Jazz Pharmaceuticals, Alnylam and Forge Biologics. Among them, Immuneel secured the most recent funding round in June, 2026.

Relation - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

AI-based drug development tools for researchers. The company has developed software for target and drug discovery. The platform leverages human genetics, single-cell omics, and perturbational data for genetic disease management.

Website: www.relationrx.com/
Social
Email ID: *****@relationrx.com

Key Metrics

Founded Year

2019

Location

London, United Kingdom

Stage

Seed

Total Funding

$116M in 5 rounds

Latest Funding Round

Seed, Nov 21, 2025, $*****

Investors

DCVC & 10 more

Ranked

44^th among 3052 active competitors

Employee Count

148 as on Sep 30, 2026

Similar Companies

Alnylam & 3650 more

View Relation's full profile

Relation is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Relation Therapeutics Ltd CIN: 12305953 , United Kingdom, Active	Nov 07, 2019	-	6 (As on Nov 30, 2020)

Relation has raised a total funding of $116M over 5 rounds. Its first funding round was on Aug 10, 2021. Its latest funding round was a Seed round on Nov 21, 2025 for $*****. 3 investors participated in its latest round. Relation has 10 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Relation:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 21, 2025	9781100	Seed	9755237	5038063	8990715	4486982
Nov 22, 2024	7678506	Seed	4248664	5082390	2671771	GSK
Jan 09, 2024	9487234	Seed	6726297	7818212	DCVC	Magnetic Ventures & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Relation's funding rounds and investors

The founders of Relation are Charles Roberts and Benjamin Swerner. David Roblin is the CEO of Relation.

Here are the details of Relation's key team members:

Charles Roberts: Co-Founder of Relation and founder of 1 other company. They are also an angel investor in 1 startup.
Benjamin Swerner: Co-Founder & COO of Relation.
David Roblin: CEO of Relation.
Contact Info: 1 email address

View details of Relation's Founder profiles and Board Members

Relation's employee count trend

Relation has 148 employees as of Sep 26. Here is Relation's employee count trend over the years:

Uncover Relation's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Relation include Jazz Pharmaceuticals, Alnylam and Forge Biologics. Here is the list of Top 10 competitors of Relation, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 14 others	81/100
3rd	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	72/100
4th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
5th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
7th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
10th	Deciphera 2003, Waltham (United States), Acquired	Developer of type 2 kinase inhibitors for treating cancer	$173M	Redmile Group, New Leaf Venture Partners & 4 others	70/100
44th	Relation 2019, London (United Kingdom), Seed	AI-based drug development tools for researchers	$116M	Deerfield, ARK Investment Management & 9 others	66/100